ACCESS Newswire

Halberd Corporation

9.8.2021 14:02:51 CEST | ACCESS Newswire | Press release

Share
Halberd Corporation's VITA-SHIELD-MAX(TM) Immunity Support Product Shipped

JACKSON CENTER, PA / ACCESSWIRE / August 9, 2021 / Halberd Corporation (OTC PINK:HALB) reports Vita-Shield-MaxTM, has been shipped! With Covid-19 cases back on the rise fueled by the Delta Variant, this "Immunity Support Nutraceutical Product" is arriving at the right time.

William A. Hartman, Halberd's Chairman, President & CEO, stated, "We will shortly begin selling Vita-Shield-MaxTM and will be releasing details on purchasing our product in the near future, once we have the product in inventory."

Halberd Corporation released a 120-page compilation of medical articles in support of its VITA-SHIELD-MAXTM Nutraceutical product earlier.

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.

Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation



View source version on accesswire.com:
https://www.accesswire.com/658881/Halberd-Corporations-VITA-SHIELD-MAXTM-Immunity-Support-Product-Shipped

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Proxymity Unveils MiKaDiv Compliance Solution for Issuers Ahead of New German Tax Regime18.11.2026 08:30:00 CET | Press release

FRANKFURT AM MAIN, DE / ACCESS Newswire / November 18, 2026 / Proxymity, the digital investor communications platform, is set to launch its MiKaDiv Compliance Solution as Germany's new dividend reporting regime takes effect in January 2027, giving German issuers a single place to manage their new obligations to the Federal Central Tax Office (BZSt). From 1 January 2027, dividends paid by listed German companies will carry an additional reporting step: the company must pass details of its shareholders to the BZSt. SRD II, transposed into German law under Section 67d of the German Stock Corporation Act, (AktG) took effect in 2020 and gave issuers the right to identify their investors, including foreign investors held through nominee accounts. MiKaDiv now makes it a requirement. The first reports are expected early in the 2027 AGM season, as issuers seek approval for their dividends. Proxymity is the leading provider of shareholder identification to German issuers, handling more than 40%

QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release

BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.

Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release

CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security

International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release

PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning

OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye